In addition, miR-17 and miR-20a targets the type II transforming growth factor β (TGF-β) receptor II whereas miR-18a targets Smad 4 downstream in the TGF-β signaling pathway, thereby opposing the tumor-suppressive effects of TGF-β and promoting angiogenesis [62]. Here, SGCG is linked to neoplasm.